Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Fission-Derived Iodine I 131 Tositumomab in NHL
NCT00062894Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2003
- Countries
- 1
- Sponsor
- GSK
- Modality
- Monoclonal Antibodies
- Conditions
- follicular lymphoma (FL)Transformed Follicular Lymphoma (tFL)
01
Overview
Phase 2, open-label, single-arm trial of iodine i 131 tositumomab in follicular lymphoma (FL) and Transformed Follicular Lymphoma (tFL), sponsored by GSK. Primary endpoint: Blood Pharmacokinetics. Started Apr 2003; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
I-131 Tositumomab
Patients receive dosimetric fission-derived I-131 Tositumomab followed by therapeutic tellurium-derived I-131 Tositumomab.
03
Who it enrols
Adult patients with previously untreated or relapsed follicular or transformed follicular lymphoma, Stage III/IV, with adequate organ function and no prior radioimmunotherapy.
04
Endpoints
Primary
Blood Pharmacokinetics
Secondary
Total Body Clearance
Tumor and Organ Dosimetry
Biodistribution
Beyond the preview
Go deeper on NCT00062894.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062894.